Anti-Arrhythmia Agents

• 

  Subject Areas on Research

  • 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 
  • 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. 
  • A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. 
  • A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. 
  • ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. 
  • ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). 
  • ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). 
  • Action potential and QT prolongation not sufficient to cause Torsade de Pointes: role of action potential triangulation. 
  • Activating PKC-β1 at the blood-brain barrier reverses induction of P-glycoprotein activity by dioxin and restores drug delivery to the CNS. 
  • Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. 
  • After myocardial infarction. How to determine future risk and what to do then. 
  • All that glitters is not gold. 
  • Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. 
  • Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. 
  • Amiodarone versus implantable cardioverter defibrillator for asymptomatic nonsustained ventricular tachycardia in nonischemic dilated cardiomyopathy. 
  • Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • An adverse reaction to a medication given to treat an adverse reaction: a teachable moment. 
  • Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. 
  • Anaphylactic reaction following intravenous adenosine. 
  • Anesthetic induction with fentanyl and intravenous lidocaine for coronary artery surgery. 
  • Anesthetic management of an AAI pacemaker patient with paroxysmal atrial fibrillation during colorectal surgery. 
  • Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction. 
  • Antiarrhythmic agents in older patients. Current state of knowledge. 
  • Antiarrhythmic drug action. Blockade of the inward sodium current. 
  • Antiarrhythmic drug action: selective depression of hypoxic cardiac cells. 
  • Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. 
  • Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease. 
  • Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). 
  • Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. 
  • Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. 
  • Ataxia caused by amiodarone in older people. 
  • Atrial fibrillation ablation alone or atrial fibrillation ablation plus an antiarrhythmic drug? 
  • Atrial fibrillation in heart failure: what should we do? 
  • Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. 
  • Atrial fibrillation: conventional wisdom reappraised. 
  • Atrial fibrillation: rate control versus maintenance of sinus rhythm. 
  • Atrial flutter, atrial fibrillation, and other primary atrial tachycardias. 
  • Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. 
  • Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. 
  • Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. 
  • Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs. 
  • Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics. 
  • Block and modulation of cardiac Na+ channels by antiarrhythmic drugs, neurotransmitters and hormones. 
  • Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells. 
  • CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift? 
  • CASE 6--2012: suspected amiodarone hepatotoxicity after cardiac surgery. 
  • CE coupling with end-column electrochemiluminescence detection for chiral separation of disopyramide. 
  • Can polymorphisms predict response to antiarrhythmic drugs in atrial fibrillation? 
  • Cardiac arrest in young, ostensibly healthy patients: clinical, hemodynamic, and electrophysiologic findings. 
  • Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. 
  • Cardiac responses to the intrapericardial delivery of metoprolol: targeted delivery compared to intravenous administration. 
  • Cardioversion and subsequent quality of life and natural history of atrial fibrillation. 
  • Cases from the Osler Medical Service at Johns Hopkins University. Digitalis toxicity with bidirectional ventricular tachycardia. 
  • Catheter Ablation Compared With Drug Therapy for Atrial Fibrillation-Reply. 
  • Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 
  • Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. 
  • Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. 
  • Cellular electrophysiology of clofilium, a new antifibrillatory agent, in normal and ischemic canine Purkinje fibers. 
  • Changes in atrioventricular conduction properties with refractory-period modulation. 
  • Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. 
  • Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. 
  • Clinical application of cardiovascular pharmacogenetics. 
  • Combination ethacizin and ethmozin treatment of resistant ventricular ectopy: theoretical, experimental, and clinical study. 
  • Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation. 
  • Comparative effectiveness of digoxin and propranolol for supraventricular tachycardia in infants. 
  • Comparative effectiveness of pharmacotherapies for prevention of atrial fibrillation following coronary artery bypass surgery. 
  • Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. 
  • Comparison of mortality in patients treated with propafenone to those treated with a variety of antiarrhythmic drugs for supraventricular arrhythmias. 
  • Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. 
  • Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs. 
  • Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? 
  • Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: a case series. 
  • Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias. 
  • Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. 
  • Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. 
  • Cryoablation for atrial fibrillation and antiarrhythmic drug pretreatment: a single referral center experience. 
  • Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. 
  • Current and novel pharmacologic approaches in advanced heart failure. 
  • Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator. 
  • Designation and distribution of events in the Multicenter UnSustained Tachycardia Trial (MUSTT). 
  • Designing clinical trials for paroxysmal atrial tachycardia and other paroxysmal arrhythmias. 
  • Dexmedetomidine: therapeutic use for the termination of reentrant supraventricular tachycardia. 
  • Differences in inducibility and prognosis of in-hospital versus out-of-hospital identified nonsustained ventricular tachycardia in patients with coronary artery disease: clinical and trial design implications. 
  • Digoxin and Mortality in Patients With Atrial Fibrillation. 
  • Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Disopyramide cross-reactivity in a commercial immunoassay reagent for methadone. 
  • Distributed decision support using a web-based interface: prevention of sudden cardiac death. 
  • Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials. 
  • Dofetilide dose reductions and discontinuations in women compared with men. 
  • Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. 
  • Double-blind randomized comparison of intravenous tocainide versus lidocaine in the treatment of chronic ventricular arrhythmias. 
  • Dronedarone in high-risk permanent atrial fibrillation. 
  • Drug Provocation Testing in Brugada Syndrome: A Test of Uncertain Significance. 
  • Drug-drug interactions in older adults: which ones matter? 
  • Early experience with intravenous sotalol in children with and without congenital heart disease. 
  • Early management of atrial fibrillation to prevent cardiovascular complications. 
  • Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. 
  • Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. 
  • Effect of amiodarone-induced hyperthyroidism on left ventricular outflow obstruction after septal myectomy for hypertrophic cardiomyopathy. 
  • Effect of dofetilide on survival in patients with supraventricular arrhythmias. 
  • Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. 
  • Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. 
  • Effects of ZD6169, a K ATP channel opener, on neurally-mediated plasma extravasation in the rat urinary bladder induced by chemical or electrical stimulation of nerves. 
  • Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation. 
  • Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. 
  • Efficacy and tolerance of Ethmozine (moricizine HCl) in placebo-controlled trials. 
  • Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. 
  • Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. 
  • Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. 
  • Electrophysiological mechanisms of the anti-arrhythmic effects of omega-3 fatty acids. 
  • Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential. 
  • Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation. 
  • Ethacizin blockade of calcium channels: a test of the guarded receptor hypothesis. 
  • Experience with moricizine HCl in children with supraventricular tachycardia. 
  • Experimental cardiac arrhythmias in the evaluation of anti-arrhythmic drugs. 
  • Exploring the role of pH in modulating the effects of lidocaine in virtual ischemic tissue. 
  • Frequency of high-risk use of QT-prolonging medications. 
  • Functional status, heart rate, and rhythm abnormalities in 521 Fontan patients 6 to 18 years of age. 
  • Get With The Guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. 
  • Helium: absence of antiarrhythmic effect in anesthetized dogs. 
  • Hemodynamic effects of the antiarrhythmic drug pirmenol. 
  • Highlights of Heart Rhythm 2005, the Annual Scientific Sessions of the Heart Rhythm Society, May 4-7, 2005, New Orleans, Louisiana. 
  • Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. 
  • Implications of the LEGACY trial on US Atrial Fibrillation Patients: An NCDR Research to Practice (R2P) Project. 
  • Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. 
  • In-hospital management of patients with atrial flutter. 
  • Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis From the STS/ACC TVT Registry. 
  • Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). 
  • Influence of gender on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia Trial. 
  • Insights into the contemporary epidemiology and outpatient management of congestive heart failure. 
  • Intentional and unintentional medication non-adherence in African Americans: Insights from the Jackson Heart Study. 
  • Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation. 
  • Investigation of potential mechanisms of sex differences in quinidine-induced torsade de pointes risk. 
  • Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes? 
  • Is newer better? Propafenone versus quinidine for conversion of atrial fibrillation. 
  • Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? 
  • Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure? 
  • Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study. 
  • Left atrial tachycardia originating from the mitral annulus-aorta junction. 
  • Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. 
  • Loss of efficacy during long-term cifenline therapy: development of antiarrhythmic resistance? 
  • MADIT-II: clinical implications. 
  • Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: a randomized controlled study. 
  • Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. 
  • Management of dofetilide overdose in a patient with known cocaine abuse. 
  • Management of pediatric tachyarrhythmias on mechanical support. 
  • Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry. 
  • Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. 
  • Mechanisms of action of antiarrhythmic drugs: from ion channel blockage to arrhythmia termination. 
  • Mechanisms of apparent affinity variation of guarded receptors. 
  • Mechanisms of atrial fibrillation and action of drugs used in its management. 
  • Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. 
  • Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. 
  • Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement? 
  • Models of drug interaction with the sodium channel. 
  • Modulating intraventricular conduction through competition of two class 1 antiarrhythmic agents: experience with ethacizin and lidocaine in canine heart. 
  • Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. 
  • Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. 
  • Mortality risk of long-term amiodarone therapy for atrial fibrillation patients without structural heart disease. 
  • Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. 
  • New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance. 
  • New drug application strategies for supraventricular arrhythmias. 
  • No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Obstructive sleep apnea is associated with increased rotor burden in patients undergoing focal impulse and rotor modification guided atrial fibrillation ablation. 
  • On the mechanism of action of antiarrhythmic agents. 
  • Ongoing Management of Patients With Supraventricular Tachycardia. 
  • Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. 
  • Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. 
  • Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation. 
  • Patient outcomes according to adherence to treatment guidelines for rhythm control of atrial fibrillation. 
  • Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. 
  • Pediatric electrophysiology. 
  • Perioperative cardiac arrhythmias. 
  • Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers. 
  • Pharmacokinetic studies: their role in determining therapeutic efficacy of agents designed to prevent sudden death. 
  • Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. 
  • Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF. 
  • Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. 
  • Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. 
  • Plasma and dietary magnesium and risk of sudden cardiac death in women. 
  • Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. 
  • Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. 
  • Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. 
  • Preoperative beta-blockade and risk of postoperative atrial fibrillation. 
  • Prevention of recurrent sudden cardiac arrest: role of provocative electropharmacologic testing. 
  • Prevention of sudden death in patients with coronary artery disease. 
  • Previously unreported adverse reaction to encainide. 
  • Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. 
  • Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. 
  • Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments. 
  • Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. 
  • Propafenone: an effective agent for the management of supraventricular arrhythmias. 
  • Prophylactic amiodarone reduces junctional ectopic tachycardia after tetralogy of Fallot repair. 
  • Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. 
  • Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. 
  • Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. 
  • Publishing web-based guidelines using interactive decision models. 
  • Pulmonary edema post-cardioversion: a potential calcium signalling problem. 
  • Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. 
  • Quality of life in patients with implantable cardioverter-defibrillator: systematic review of randomized controlled trials. 
  • Quality of life with defibrillator therapy or amiodarone in heart failure. 
  • Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. 
  • Ranolazine reduces atrial fibrillatory wave frequency. 
  • Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery. 
  • Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. 
  • Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. 
  • Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. 
  • Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. 
  • Regional anesthesia for thyroidectomy in two patients with amiodarone-induced hyperthyroidism. 
  • Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial. 
  • Reply: Digoxin Use in Atrial Fibrillation: Minimizing and Refining its Use When Still Needed. 
  • Rethinking papillary muscle resection for refractory ventricular tachycardia in the LVAD era. A case report. 
  • Review: In noncardiac surgery, amiodarone, β-blocker, or statin prophylaxis reduces postoperative AF. 
  • Rhythm control in atrial fibrillation. 
  • Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation. 
  • Rhythm control versus rate control for atrial fibrillation and heart failure. 
  • Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital. 
  • Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. 
  • SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death. 
  • Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. 
  • Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998. 
  • Several new considerations in mitral valve repair. 
  • Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. 
  • Sinus node dysfunction. 
  • Slow sodium channel inactivation and use-dependent block modulated by the same domain IV S6 residue. 
  • State dependence of ethacizin and ethmozin block of sodium current in voltage clamped and internally perfused cardiac Purkinje cells. 
  • Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines - Heart Failure Program). 
  • Supraventricular tachycardia in four young dogs. 
  • Surgical Maze procedure as a treatment for atrial fibrillation: a meta-analysis of randomized controlled trials. 
  • Surrogate end points in heart failure trials. 
  • Sympathectomy for Stabilization of Heart Failure Due to Drug-Refractory Ventricular Tachycardia. 
  • Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. 
  • The cardiac sodium channel: a target for antiarrhythmic drug action. 
  • The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias. 
  • The effect of bretylium tosylate on ventricular function. 
  • The effect of quinidine, propranolol and their combination on experimental atrial and ventricular arrhythmias. 
  • The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. 
  • The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. 
  • The management of acute coronary insufficiency. 
  • The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. 
  • Thyroid function in heart failure and impact on mortality. 
  • To be or not to be in normal sinus rhythm: what do we really know? 
  • Treatment of supraventricular tachycardia in infants: Analysis of a large multicenter database. 
  • Treatment of tachyarrhythmias. 
  • Trends Over Time in Drug Administration During Adult In-Hospital Cardiac Arrest. 
  • Update on sick sinus syndrome, a cardiac disorder of aging. 
  • Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. 
  • Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. 
  • Use of amiodarone after major lung resection. 
  • Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. 
  • Use of implantable cardioverter defibrillator and anti-arrhythmic agents in a parturient. 
  • Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Verapamil prolongs atrial fibrillation by evoking an intense sympathetic neurohumoral effect. 
  • Verapamil treatment for women with bipolar disorder. 
  • Wavelet formation in excitable cardiac tissue: the role of wavefront-obstacle interactions in initiating high-frequency fibrillatory-like arrhythmias. 
  • What happens when cardiac Na channel function is compromised? 2. Numerical studies of the vulnerable period in tissue altered by drugs. 
  • What to do with acute atrial fibrillation? 
  • When the body and appendage of the left atrium disagree: "Focal" atrial fibrillation-implications for atrial thrombus formation and risk of thromboembolism. 
  • Who are the MADIT patients? Multicenter Automatic Defibrillator Implantation Trial. 
  • Wolff-Parkinson-White syndrome in infants. 
  • [Guidelines for the management of patients with atrial fibrillation. Executive summary]. 
  • [Severe intrahepatic cholestasis in a 66-year old male patient with medically treated atrial fibrillation]. 
  • [The combined effect of 2 first-line anti-arrhythmia drugs on the conduction velocity of myocardial stimulation]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Starmer, Charles Franklin, Professor Emeritus of Computer Science, Computer Science
  • Warner, David Samuel, Distinguished Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology